AMRN

Amarin

• Seeking Alpha·4d ago

  Amarin: The Market Is Pricing A 55% Chance Of A Sale That Isn't Coming

• Benzinga·4d ago

  12 Health Care Stocks Moving In Tuesday's Pre-Market Session

• NASDAQ·07/01 09:06

  AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)

• Benzinga·06/30 20:18

  Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As Triglycerides Greater Than Or Equal To 500 mg/dL

• PUBT·06/11 12:45

  Palisade Bio adds Robert Baltera, Jordan Zwick to board of directors

• NASDAQ·06/05 05:34

  U.S. Supreme Court Ends Amarin Patent Fight, Hikma Prevails

• PUBT·06/04 19:33

  US Supreme Court ends Amarin patent suit against Hikma over generic Vascepa

• Seeking Alpha·06/04 17:46

  Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics

• Benzinga·06/04 14:10

  U.S. Supreme Court Rules In Favor Of Hikma Pharmaceuticals V Amarin Pharmaceuticals Over Patent Infringement Claims By Amarin

• Reuters·06/04 14:01

  U.S. SUPREME COURT RULES IN FAVOR OF GENERIC DRUGMAKER HIKMA IN 'SKINNY LABEL' PATENT DISPUTE OVER AMARIN HEART DRUG VASCEPA

• NASDAQ·05/28 07:30

  Amarin Presents RW-ApoB As Risk Identifier For Cardiovascular Disease Based On REDUCE-IT Data

• PUBT·05/27 12:04

  Amarin post hoc REDUCE-IT analysis says risk-weighted apoB better flags residual CV risk in statin-treated patients

• Benzinga·05/27 12:03

  Amarin Announces New Data From A Post Hoc Analysis Of The REDUCE-IT Trial; Apolipoprotein B More Effectively Identified Individuals At Increased Residual Cardiovascular Risk

• TipRanks·05/15 10:30

  Amarin Shareholders Reject Dilution, Governance Proposals at AGM

• PUBT·05/15 10:18

  Amarin shareholders reject share issuance authorization at annual meeting